Definium Therapeutics, Inc. (DFTX) Cash Flow Statement
Where DFTX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$131.6M
- Capital expenditures
- $0
- Free cash flow
- −$131.6M
- Returned to shareholders
- —
- Change in cash
- −$15.9M cash at year-end $257.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
DFTX operating cash flow, capex and free cash flow
DFTX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$26,6362016 | −$131.6M2025 | — | |
| Capital expenditures | $30,0982016 | $02025 | −100.0% | |
| Free cash flow | −$56,7342016 | −$131.6M2025 | — | |
| Stock-based compensation | $7.4M2020 | $20.1M2025 | +22.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
DFTX cash flow by activity
DFTX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
DFTX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$183.8M | −$108.7M | −$95.7M | −$56.8M | −$93.0M | −$33.9M | −$1.1M | −$857,944 | −$1.2M | −$179,900 |
| Depreciation & amortization | $0 | $527,000 | $3.2M | $3.2M | $2.6M | — | $6,684 | $6,682 | $5,501 | — |
| Stock-based compensation | $20.1M | $16.9M | $15.5M | $13.7M | $42.7M | $7.4M | — | — | — | — |
| Change in working capital | $9.4M | −$3.3M | $6.3M | −$3.8M | $1.9M | $2.1M | $207,826 | −$20,464 | −$81,759 | $62,619 |
| Other non-cash items | $22.7M | $15.5M | $6.4M | −$6.4M | $0 | $873,000 | $693,177 | $149,275 | $637,007 | $90,645 |
| Cash from operating activities | −$131.6M | −$79.1M | −$64.4M | −$50.1M | −$45.8M | −$23.6M | −$208,119 | −$722,451 | −$665,984 | −$26,636 |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | −$313,457 | −$1.0M | −$2.1M | −$30,098 |
| Investments (net) | −$151.6M | $0 | — | — | — | — | — | — | — | — |
| Acquisitions & other investing | $0 | — | — | — | −$297,000 | — | $100,304 | $1.6M | −$1.5M | $62,923 |
| Cash from investing activities | −$151.6M | — | — | — | −$297,000 | — | −$213,153 | $541,335 | −$3.7M | $32,825 |
| Financing activities | ||||||||||
| Net borrowing (repayment) | $20.0M | $10.9M | $21.7M | $0 | — | — | — | — | — | — |
| Shares issued | $258.9M | $250.0M | $0 | $42.3M | $81.9M | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$11.6M | −$7.7M | $163,000 | $16.8M | $16.9M | $96.7M | $288,363 | $312,051 | $4.4M | −$331 |
| Cash from financing activities | $267.3M | $253.2M | $21.8M | $59.1M | $98.8M | $96.7M | $288,363 | $312,051 | $4.4M | −$331 |
| Summary | ||||||||||
| Net change in cash | −$15.9M | $174.0M | −$42.4M | $8.6M | $53.4M | $73.4M | −$136,860 | $150,813 | −$6,984 | $5,858 |
| Cash at end of period | $257.8M | $273.7M | $99.7M | $142.1M | $133.5M | $80.1M | $17,931 | $154,791 | $3,978 | $10,962 |
| Free cash flow | −$131.6M | −$79.1M | −$64.4M | −$50.1M | −$45.8M | −$23.6M | −$521,576 | −$1.8M | −$2.8M | −$56,734 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$159.0M | −$77.1M | −$50.4M | −$67.3M | −$42.7M | −$23.3M | −$34.7M | −$13.7M | −$5.9M | −$54.4M | −$23.9M | −$17.9M |
| Depreciation & amortization | −$631,000 | $631,000 | $0 | $6,750 | $0 | $0 | $0 | $0 | — | $527,000 | $790,000 | $791,000 |
| Stock-based compensation | $9.6M | $7.1M | $11.4M | $5.8M | $5.3M | $3.4M | $3.4M | $3.8M | $5.4M | $3.7M | $3.7M | $4.2M |
| Change in working capital | $6.3M | $5.4M | −$4.5M | $8.1M | $8.1M | −$2.5M | −$225,000 | $4.1M | −$3.5M | −$677,000 | −$3.8M | −$1.1M |
| Other non-cash items | $90.9M | $21.3M | $1.6M | $23.8M | −$197,000 | −$7.0M | $6.2M | −$11.4M | −$16.1M | $34.3M | $2.6M | −$2.6M |
| Cash from operating activities | −$52.8M | −$42.6M | −$41.9M | −$29.6M | −$29.6M | −$29.4M | −$25.4M | −$17.2M | −$20.0M | −$16.6M | −$20.6M | −$16.6M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | −$316.7M | $42.0M | $35.0M | $15.4M | −$39.5M | −$162.5M | — | $0 | — | — | — | — |
| Acquisitions & other investing | $0 | $0 | $2.5M | $0 | $0 | $0 | — | — | — | — | — | — |
| Cash from investing activities | −$316.7M | $42.0M | $37.5M | $15.4M | −$39.5M | −$162.5M | — | — | — | — | — | — |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | $0 | $447,000 | $19.6M | $0 | $984,000 | $128,000 | — | — | — | — |
| Shares issued | $804.7M | $276,000 | $258.9M | $0 | $0 | $186,000 | $0 | $75.0M | $0 | $0 | $0 | $0 |
| Other financing | −$42.5M | $5.0M | −$12.2M | $302,000 | $97,000 | $816,000 | $2.8M | −$5.8M | $10.8M | $169.2M | $2.6M | $17.4M |
| Cash from financing activities | $762.3M | $5.3M | $246.6M | $749,000 | $19.6M | $1.0M | $3.8M | $69.4M | $10.8M | $169.2M | $2.6M | $17.4M |
| Summary | ||||||||||||
| Net change in cash | $392.7M | $4.7M | $237.9M | −$13.4M | −$49.5M | −$190.9M | −$21.5M | $52.2M | −$9.2M | $152.6M | −$18.0M | $804,000 |
| Cash at end of period | $655.3M | $262.5M | $257.8M | $20.0M | $33.4M | $82.9M | $273.7M | $295.3M | $243.1M | $252.3M | $99.7M | $117.7M |
| Free cash flow | −$52.8M | −$42.6M | −$41.9M | −$29.6M | −$29.6M | −$29.4M | −$25.4M | −$17.2M | −$20.0M | −$16.6M | −$20.6M | −$16.6M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
DFTX cash generation
In fiscal 2025 (ended December 31, 2025), Definium Therapeutics generated -$131.6 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$131.6 million. Cash and equivalents fell by $15.9 million over the year.
Related: DFTX income statement, DFTX balance sheet. See the DFTX stock overview for the latest quote and news.
DFTX cash flow FAQ
What is Definium Therapeutics's free cash flow?
Definium Therapeutics's free cash flow was -$131.6 million in fiscal 2025: -$131.6 million of operating cash flow minus $0 of capital expenditures It was -$79.1 million a year earlier..
How much cash does Definium Therapeutics generate from operations?
Definium Therapeutics generated -$131.6 million of cash from operating activities in fiscal 2025.